**6. References**


[10] Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and

[11] Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic

[13] Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ. c7E3 Fab inhibits

[14] Neumann FJ, Blasini R, Schmitt C. Effect of glycoprotein IIb/IIIa receptor blockade on

[15] Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M,

[16] Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Role of activation-

[17] Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation

[18] Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-356 [19] Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and

[20] Bates ER, Lau WC. Controversies in antiplatelet therapy for patients with

[21] Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin

[22] Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the

[23] Tantry US, Bliden KP, Gurbel PA. Prasugrel. Expert Opin Investig Drugs 2006;15:1627-

[24] Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading

[25] The CLEAR PLATELETS Investigators. Gurbel PA, Bliden KP, Zaman KA, Yoho JA,

relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S-

dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.

Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159

coronary stent thrombosis. Coron Artery Dis 1997;8:121-128

[12] Ito H. No reflow phenomenon in coronary heart disease. J Cardiol 2001;37:39-42

implications. Circulation 1989;80:198-205

myocardium. Cardiovasc Res 2004;61:498-511

controls. Thromb Haemost 2000;83:217-223

stenting. J Am Coll Cardiol 1996;27:15-21

Semin Thromb Hemost 1999;25:15-19

halve not. J Am Coll Cardiol 2000;35:1808-1812

cardiovascular disease. Circulation 2005;111:267-271

Cardiol 2000;35:915-921

Invest 2004;113:340-345

264S

1633

unstable coronary artery lesions. Experimental evidence and potential clinical

low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy

recovery of coronary flow and left ventriculkar function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701

Schleef M, Seyfarth M, Dirschinger J, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll

dependent platelet membrane glycoproteins in development of subacute occlusive

of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz


[37] Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine

[39] The PRINCIPLE-TIMI 44 Investigators. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue

[40] The TRITON-TIMI 38 Investigators. Montalescot G, Wiviott SD, Braunwald E, Murphy

[41] Freeman MK. Thienopyridine antiplatelet agents: focus on prasugrel. Consult Pharm

[42] The CHARISMA Investigators. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao

Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373

trial. J Am Coll Cardiol 2011;57:672-684

[44] The PLATO Investigators. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP,

[45] Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE,

genotype: first experience in patients. J Thromb Haemost 2010;8:43-53 [46] The INNOVATE-PCI Investigatos. Leonardi S, Rao SV, Harrington RA, Bhatt DL,

Pharmacol 2010;50:126-142. Erratum in J Clin Pharmacol 2010;50:483 [38] Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma

subjects. J Cardiovasc Pharmacol 2006;47:377-384

Circulation 2007;116:2923-2932

trial. Lancet 2009;373:723-731

2010;25:241-257

antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin

H, Li GY, Winters KJ. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy

M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

SA, Gibson CM, McCabe CH, Antman EM. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled

M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ; CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010;121:2575-2583 [43] The JUMBO-TIMI 26 Investigators. Wiviott SD, Antman EM, Winters KJ, Weerakkody

G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets

Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes)

Shuldiner AR, Conley PB, Tantry US. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19\*2

Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD,

McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010;160:65-72


Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-84, Erratum in Lancet Neurol 2008;7:985


study. Lancet Neurol 2008;7:875-84, Erratum in Lancet Neurol 2008;7:985 [58] The ACCEL-AMI Investigators. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee

[59] The DECREASE Investigators. Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ,

[60] Kozlowski EO, Pavao MS, Borsig L. Ascidian dermatan sulfates attenuate metastasis,

[61] Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and

[62] Di Minno MN, Prisco D, Ruocco AL, Mastronardi P, Massa S, Di Minno G.

[63] Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG; Canadian Acute

[64] Picker SM, Kaleta T, Hekmat K, Kampe S, Gathof BS. Antiplatelet therapy preceding

[65] Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo

[66] Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R,

implantation of drug-eluting stents. JAMA 2005;293:2126-2130

participant data from randomised trials. Lancet 2009;373:1849-1860

Cardiovasc Interv 2010;3:17-26

2011;1111:1538-7836

2005;150:690-694

Thromb Res 2008;122:786-803

Intern Emerg Med 2009;4:279-288

outcome. Eur J Anaesthesiol 2007;24:332-329

(DECREASE registry). Am Heart J 2010;159:284-291

Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled

SW, Kwak CH, Park SW. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ

Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cadiac Events

inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost

antagonism: emerging approaches for the prevention of intravascular thrombosis.

Perioperative handling of patients on antiplatelet therapy with need for surgery.

Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J

coronary artery surgery: implications for bleeding, transfusion requirements and

A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful

Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual


[79] The COMMIT Investigators. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R,

[80] Hart RG, Bhatt DL, Hacke W, Fox KA, Hankey GJ, Berger PB, Hu T, Topol EJ.

[81] Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ.

[82] The TAMI 8 Investigators. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D,

[83] The TIMI 14 Investigators. Antman EM, Gibson CM, de Lemos JA, Giugliano RP,

[84] The IMPACT-AMI Investigators. Ohman EM, Kleiman NS, Gacioch G, Worley SJ,

[85] The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein

[86] The GUSTO V Investigators. Topol EJ. Reperfusion therapy for acute myocardial

[87] Fernandez JS, Sadaniantz BT, Sadaniantz A. Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis 2003;42:446-455 [88] The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before

randomized trial. Cerebrovasc Dis 2008;25:344-347

Arteries. J Am Coll Cardiol 1998;31:1466-1473

Study. J Am Coll Cardiol 1993;22:381-289

trial. J Am Coll Cardiol 1998;32:2003-2010

study. Lancet 1997;349:1429-1435

2005;366:1607-1621

2000;21:1944-1953

1997;95:846-854

2001;357:1905-1914

Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet

Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA

Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary

Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot

McCabe CH, Coussement P, Menown I, Nienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E. Combination reperfusion therapy with abciximab and reduced dose reteplase: results the Thrombolysis in Myocardial Infarction (TIMI) 14 study. Eur Heart J

Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation

IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM)

infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet

and during coronary intervention in refractory unstable angina: the CUPTURE


[100] The GUSTO IV-ACS Investigators. Simoons ML. Effect of glycoprotein IIb/IIIa

[101] The RAPPORT Investigators. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS,

[102] The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with

[104] The TACTICS Investigators. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R,

[105] The TARGET Investigators. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines

[106] Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones

Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374 [107] Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer

IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887

Engl J Med 2001;344:1888-1894

2004;126:513S-548S

Lancet 2001;357:1915-1924

1998;98:734-741

973

receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT). Circulation

tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-1453 [103] The IMPACT-II Investigators. Blankenship JC, Sigmon KN, Pieper KS, O'Shea C,

Tardiff BE, Tcheng JE. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT-II Trial-(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II Trial). Am J Cardiol 2001;88:969-

Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein

CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N

RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina.ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of

DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest

